Genetics Shape GLP 1 Response and Heart Benefits

In April 2026, recent studies highlight how genetic variations influence responses to GLP-1 obesity drugs, reveal independent heart benefits, and demonstrate the powerful role of non-coding DNA in development.

Key Points

GLP-1 Drugs & Genetics:
- Study by 23andMe on ~28,000 users.
- Variants in GLP1R gene linked to improved weight-loss response.
- Carriers lost up to 3.3 pounds more than non-carriers.
Side Effects & Genes:
- Variants in GLP1R and GIPR genes linked to nausea and vomiting.
- Strong association seen with Tirzepatide.
- Carriers 83% more likely to experience vomiting.
Precision Medicine Insight:
- Genetic variation explains differences in drug response.
- Supports personalised treatment approaches for obesity.
Heart Benefits of GLP-1 Drugs:
- Study on 47,199 patients using Semaglutide.
- Higher doses linked to lower risks of heart disease and death.
- Benefits independent of weight loss levels.
Scientific Finding:
- GLP-1 receptors found significantly in heart tissue.
- Suggests direct cardiac effects beyond weight reduction.
DNA Mutation Breakthrough:
- Single mutation in non-coding DNA triggered sex reversal in mice.
- Mutation affected Sox9 gene regulation.
Role of Non-Coding DNA:
- Non-coding genome (98% of DNA) regulates gene activity.
- Even tiny changes can cause major developmental outcomes.
Medical Implications:
- Insights for Differences of Sex Development (DSD).
- Highlights need to study beyond protein-coding genes.